yes/no answer, whereas quantitative real-time PCR, MethyLight qMSP, and pyrosequencing provide the frequency of methylation for the examined CpG sites (14) (15) (16) (17) (18) (19) (20) 23) .
Meningiomas are most often benign, intracranial neoplasms that can be cured by surgery alone (24) . However, some of these tumors are more aggressive, such as highgrade meningioma, or may be inoperable because of their location, or may recur even in the absence of histological signs of atypia (25) . Histopathological grading of these neoplasms, along with the presence or absence of postoperative residual tumor, is used to estimate the risk of recurrence and, hence, the need for further tumor management (24, (26) (27) (28) . The decision whether or not to irradiate the neoplastic lesion is of particular interest as radiotherapy carries the risk of side-effects. Therefore, refinement of stratification criteria is warranted (24, (26) (27) (28) .
In 2004, Chamberlain et al. (29) reported a prospective phase II study of temozolomide which was conducted on 16 patients with refractory meningioma. None of the patients showed complete or partial neuroradiographic response. In the same year, using MSP methodology, Bello et al. studied the promoter-methylation status of 10 tumor-related genes, among them MGMT, in a series of 98 meningiomas. The promoter of MGMT was found to be methylated in 16 out of the 98 examined meningiomas (30) .
To date, the methylation status of the promoter region of MGMT in meningiomas has been examined in eight published studies (30) (31) (32) (33) (34) (35) (36) (37) . Table I summarizes their results and the methodology used in these studies. In six of them, only few meningiomas (up to 6%) had methylated MGMT promoter. However, in two studies, methylated MGMT promoter was found in 16% (30) and 34% of meningiomas (36) . In six of the published works, MSP methodology was used (30) (31) (32) (33) (34) 36) . In the seventh study, a methylation-specific and SYBR-green-based quantitative PCR technique was used (36) , whereas in the eighth, targeted bisulfite sequencing was performed to detect MGMT promoter methylation (37) . For the MSP methodology, the primers described by Esteller et al. (7) were used in five of the published works (30-32, 34, 36) , whereas the primers described by Beier et al. (38) were used in the sixth study (33) (Figure 1 ).
In the present study, pyrosequencing was used to determine the MGMT gene promoter methylation frequencies in 61 meningiomas. Pyrosequencing is regarded as a very robust technique for analysis of MGMT promoter methylation and its clinical utility has been validated in several independent studies (15-18, 20, 39, 40) . Pyrosequencing provides the frequency of methylated alleles of each CpG site analyzed whereupon the mean of the different sites is used to classify tumors as 'methylated' or 'unmethylated' (40, 41) . The Therascreen MGMT Pyro Kit (Qiagen, Hilden, Germany) which was used in the present study, has been tested and validated; it has shown a strong analytical performance (40, 41) Figure 1 ).
Materials and Methods

Patients
Research Ethics South-East Norway (S-06046) and written informed consent to publication of the case details was obtained from all patients. The Ethics Committee's approval included a review of the consent procedure. All patient information has been de-identified.
DNA isolation and bisulfite conversion. Genomic DNA was extracted from tumor samples using the Maxwell 16 Instrument System and the Maxwell 16 Tissue DNA Purification Kit (Promega, Madison, WI, USA). The concentration and purity of DNA were measured using a NanoVue Plus Spectrophotometer (GE Healthcare Life Sciences, Oslo, Norway). Unmethylated cytosine residues were converted to uracil by bisulfite treatment of 500 ng DNA using the EpiTect Bisulfite Kit (Qiagen, Hilden, Germany) and the QiaCube automated purification system (Qiagen) according to the manufacturer's recommendations. According to the company's information, the limit of blank values represent methylation frequencies obtained from healthy blood donor samples with a probability of 95%: 1.5, 1.8, 3.2, and 3.4 for CpG sites 1, 2, 3, and 4, respectively (mean for CpG sites 1 to 4=2.5). In our assays, the cut-off frequency for accepting methylation as positive for all four CpG sites was set to 10%.
Results
The methylation frequencies of the four analyzed CpG sites in exon 1 of MGMT in the 61 meningiomas are presented in Table II . In only two tumors was the mean methylation frequency of the four CpG sites higher than 10%. In case 18, which was an atypical meningioma, the mean methylation frequency was 33% and it was higher than 30% for all four CpG sites. In case 37, which was a grade I meningioma, the mean methylation frequency was 17%, but with marked differences among the four CpG sites: CpG site 1 had the highest methylation frequency (43%), followed by site 2 (13%), site 4 (8.5%), and site 3 (6.0%). The other meningiomas with histomorphological signs of aggressiveness, including six atypical and one anaplastic meningioma, had a methylation frequency of below 10.0%, similarly to the other 52 grade I meningiomas.
Discussion
Our results suggest that the methylation frequency of the MGMT gene promoter in general is low in meningiomas, with 59 tumors (97%) having a mean methylation frequency at the four examined CpG sites of below 7%. These data are in line with previous studies that described no MGMT promoter methylation or a low frequency using MSP or targeted bisulfite sequencing methodologies (31-33, 35, 37) .
The two cases with methylated MGMT promoter, i.e., for which the mean methylation frequency of the four CpG sites was higher than 10%, had different methylation patterns for the four CpG sites. In the atypical meningioma (case 18, grade II tumor), the methylation frequency was higher than 30% for all four CpG sites. In the grade I meningioma (case 37), the methylation frequencies among the four CpG sites showed marked differences: CpG site 1 had the highest methylation frequency (43%), followed by site 2 (13%), site 4 (8.5%), and site 3 (6.0%). Bujko and Kober (37), using targeted bisulfite sequencing, reported a high methylation frequency (of over 75%) for single CpGs within the MGMT promoter region in five tumor samples. However, the average methylation level for the entire region was very low in those samples.
Bello et al. (30) , Aydemir et al. (34) , and Larijani et al. (36) found that the MGMT promoter was methylated in 16%, 11%, and 34% of the examined meningiomas, respectively. In these three studies, the same principal methodology was used, namely MSP with primers published by Esteller et al. (7) . In contrast, and using the same method as above, Liu et al. (31) and de Robles et al. (32) showed that the promoter of MGMT was methylated in 6% and 0% of their examined meningiomas. Jabini et al. (35) used quantitative MSP, but again with the primers used by Esteller et al. (7) , finding that none of 230 examined meningiomas had methylated MGMT promoter. The reason behind the reported differences in the frequency of methylated menigiomas, measured using the same MSP methodology, is unknown. MSP does produce false-positive as well as false-negative results under some circumstances, especially when performed on DNA of low quality or quantity, including DNA extracted from formalinfixed and paraffin-embedded tissue (15, (42) (43) (44) . In addition, mosaic methylation patterns and incomplete bisulfite conversion may lead to mispriming and lower sensitivity and specificity (15, (42) (43) (44) (45) (46) (47) .
Based on the results of our study and taking into consideration the already published data, amounting to 643 meningiomas altogether, we conclude that the methylation frequency of the MGMT promoter in meningioma is low (6%). Consequently, there is no convincing rationale for testing such tumors for their MGMT methylation status in a clinical setting.
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